Treatment
Patients will receive clinical trials
We’re tracking 291 recruiting studies that include Patients will receive, each written for real people, not researchers, below.
Recruiting studies
- NCT07740694Recruiting
ECT study for older adults with depression
This study looks at how ECT affects brain activity and inflammation in older adults with depression. It may help researchers understand why ECT works and improve treatment.
Istanbul, BakırköyAges 55 years+ - NCT06662058Recruiting
Remote hearing test for head and neck cancer patients on cisplatin or radiation
This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.
Atlanta, GeorgiaAges 18 years+ - NCT04331639Recruiting
High-dose vitamin D for kids with IBD on biologic therapy
This trial studies whether giving a higher dose of vitamin D3 helps children and teens with inflammatory bowel disease (Crohn’s or ulcerative colitis) who have low vitamin D levels. Participants are already on biologic medicines and will be treated while monitoring blood (and safety) related to vitamin D.
Boston, MassachusettsAges 5–25 - NCT05183646RecruitingPhase 3
DMX-200 for FSGS in people taking an ARB medicine
This Phase 3 trial studies whether DMX-200 is safer and works better than placebo for people with FSGS who are already on (or can switch to) an ARB blood-pressure/kidney-protection medicine. It also looks at side effects over a long follow-up period.
Birmingham, AlabamaAges 12–80 - NCT06514976Recruiting
Study of Cytoflavin for ischemic stroke without clot treatment
This study is testing a medicine called Cytoflavin for people who have had a recent ischemic stroke but are not receiving clot-busting treatment. It aims to see if Cytoflavin helps improve recovery compared to other treatments or no treatment.
IvanovoAges 18 years+ - NCT06660719RecruitingPhase 3
New stroke medicine SP-8203 with clot-busting therapy
This trial tests a new medicine called SP-8203 added to standard clot-busting treatment for people having a moderate to severe stroke. The goal is to see if it helps improve recovery and is safe.
BusanAges 19–85 - NCT06728891Recruiting
Analyzing tumor deposits after stomach cancer surgery
This study looks at cancer cell deposits found in the area where the right and left stomach-supporting tissues meet, after surgery for stomach cancer. It may help doctors understand how cancer spreads and improve future treatment.
Hangzhou, ZhejiangAges 18–85 - NCT06902467Recruiting
Chemotherapy directly into the abdomen after surgery for advanced ovarian cancer
This trial tests giving chemotherapy directly into the abdomen (intraperitoneal) after optimal surgery for advanced ovarian cancer. It aims to see if this approach is safe and effective for women who have already received 3-4 cycles of chemotherapy before surgery.
MurciaAges 18–70 - NCT07134842RecruitingPhase 1
Immunotherapy before standard brain cancer treatment
This trial tests giving the immunotherapy drug ipilimumab before the usual treatment for newly diagnosed glioblastoma (a type of brain cancer). The goal is to see if this approach is safe and possible, and whether it might help the immune system fight the tumor better.
London, Greater LondonAges 18 years+ - NCT07526987RecruitingPhase 3
Minocycline to Help Recovery After Acute Stroke Treatment
This study tests whether an antibiotic called minocycline, given alongside standard stroke treatment (clot-busting medication), can help reduce brain damage and improve recovery. You would receive minocycline around the time of your clot-busting treatment.
Liaocheng, ShandongAges 18–80 - NCT02610426Recruiting
Genetic testing to study who develops heart failure during breast cancer therapy
This study uses DNA genetic testing to find DNA changes that might explain why some people develop heart failure (CHF) after breast cancer treatment with certain medicines. It may help researchers understand risk and improve care for future patients.
Boston, MassachusettsAges Any age - NCT07676461Recruiting
Microbiome study in advanced cancer patients starting immunotherapy
This study looks at the bacteria in your mouth, gut, and tumors to see if they affect how well first-line immunotherapy works. It is for people with advanced stomach, colorectal, breast, cervical, or head-and-neck cancer.
Bogotá, Bogota D.C.Ages 18 years+ - NCT07669454RecruitingPhase 3
Nuvastatic® for metastatic colorectal cancer
This trial tests a new capsule (Nuvastatic®) added to standard chemotherapy for people with metastatic colorectal cancer. The goal is to see if it helps shrink tumors and improve well-being.
Visakhapatnam, Andhra PradeshAges 18–65 - NCT06204406Recruiting
Kidney-sparing treatment for upper tract urothelial cancer
This study looks at how well patients do when they have kidney-sparing treatment (instead of complete kidney removal) for upper tract urothelial carcinoma. It helps doctors understand which patients can safely avoid losing their kidney.
Shanghai, Shanghai MunicipalityAges 18–90 - NCT07754253RecruitingPhase 1
Green tea extract for gum disease treatment
This trial tests a green tea extract (EGCG) as an add-on to standard gum disease treatment, delivered locally to the gums. It aims to see if this natural compound can help improve gum health more effectively than standard care alone.
Al Mansurah, Dakahlia GovernorateAges 25–60 - NCT04160429Recruiting
Biospecimen testing to measure chemicals during treatment
This trial collects small samples like blood, sweat, and saliva while you’re taking certain medicines. Researchers will analyze these samples to see if they can detect chemical levels, which may help improve monitoring for people with chronic or infection-related illnesses.
Duarte, CaliforniaAges 18 years+ - NCT04997096Recruiting
Exercise during chemo to prevent weakness from low movement
This study tests whether a structured exercise program during chemotherapy can help prevent physical decline (“immobility,” like getting weaker or moving less) in people with certain ovarian or endometrial cancers. If you’re eligible, you may be guided to exercise while receiving standard chemo, and you’ll have blood tests to track changes.
Boston, MassachusettsAges 18 years+ - NCT05998928RecruitingPhase 2
BCMA-GPRC5D CAR-T for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (CAR-T) that targets two proteins on myeloma cells for patients whose cancer has returned or not responded after at least three prior treatments. It aims to see if this therapy is safe and effective.
Wuhan, HubeiAges 18–75 - NCT06866964RecruitingPhase 2
Aspirin to prevent blood clots in advanced germ cell cancer chemotherapy
This trial tests if daily aspirin can prevent dangerous blood clots in people receiving chemotherapy for advanced testicular or germ cell cancer. It is for those at high risk of clots and aims to improve safety during treatment.
Charlotte, North CarolinaAges 18–70 - NCT07161310Recruiting
Urolithin A with immunotherapy for newly diagnosed solid tumors
This trial tests adding a natural supplement called urolithin A to standard first-line immunotherapy for people with newly diagnosed solid tumors who have not yet had any cancer treatment. The goal is to see if it makes the immunotherapy work better.
FrankfurtAges 18 years+ - NCT07192185RecruitingPhase 2
Chemo plus immunotherapy for advanced liver cancer after first treatment fails
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
Guangzhou, GuangdongAges 18–75 - NCT06600659Recruiting
Ammonia levels after asparaginase in children
This study looks at how many children develop high ammonia levels after receiving a cancer medicine called recombinant Erwinia asparaginase. It helps doctors understand side effects and keep patients safe.
Rochester, MinnesotaAges 1 year+ - NCT07585097Recruiting
Long-term Safety Study of Odevixibat for Alagille Syndrome
This study follows patients with Alagille syndrome who are taking odevixibat to see how safe the medicine is over time. Alagille syndrome is a rare liver disease that affects bile flow, and odevixibat is a treatment that may help reduce itching and improve liver function.
BronAges 6 months+ - NCT06850038Recruiting
Long-term study of odevixibat in Alagille syndrome
This study follows people with Alagille syndrome who are already taking or starting odevixibat (Bylvay). It looks at how well the medicine works and how safe it is over a long period of time.
Los Angeles, CaliforniaAges Any age
Common questions
- Are there clinical trials studying Patients will receive?
- Yes. Clin2 currently lists 291 recruiting studies that include Patients will receive, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Patients will receive trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Patients will receive an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Patients will receive or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.